Lineage Cell Therapeutics
LCTX
129 hedge funds and large institutions have $88.4M invested in Lineage Cell Therapeutics in 2025 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 23 increasing their positions, 35 reducing their positions, and 32 closing their positions.
78% more capital invested
Capital invested by funds: $49.7M → $88.4M (+$38.7M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
2% more funds holding
Funds holding: 127 → 129 (+2)
9% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 32
5.07% less ownership
Funds ownership: 47.89% → 42.82% (-5.1%)
34% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.54M |
| 2 |
Comerica Bank
Dallas,
Texas
|
+$949K |
| 3 |
Jane Street
New York
|
+$853K |
| 4 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
+$715K |
| 5 |
DC
Defender Capital
Charlotte,
North Carolina
|
+$281K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$5.45M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.22M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.13M |
| 4 |
State Street
Boston,
Massachusetts
|
-$1.07M |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$610K |
LCTX Hedge Fund Activity: Q2 2025 in Review
129 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2025, worth a combined $88.4M — up 78% from $49.7M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new LCTX positions and 32 closed out — a net gain of 3 holders — while 23 added to existing stakes and 35 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $1.54M. The largest seller was BlackRock, cutting an estimated $5.45M.
- 129 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2025, up from 127 in Q1 2025.
- Funds reported $88.4M of Lineage Cell Therapeutics stock for Q2 2025, up 78% quarter-over-quarter.
- 35 funds opened new Lineage Cell Therapeutics positions in Q2 2025 and 32 closed out, a net change of +3 holders.
- The largest Lineage Cell Therapeutics buyer in Q2 2025 was Millennium Management, an estimated $1.54M added.
- The largest Lineage Cell Therapeutics seller in Q2 2025 was BlackRock, an estimated $5.45M sold.
Based on aggregated 13F filings for Q2 2025.